Overview of the Hospital Inpatient Free Trial Program (HIFTP) Terms & Conditions
Below are highlights from the complete terms and conditions that hospitals and pharmacists must accept before they can participate in the Hospital Inpatient Free Trial Program for WELTRUZA (the “Program”).
- WELTRUZA (olanzapine) (“Program Product”) is available only to hospital pharmacies, hospital-certified pharmacies, crisis stabilization units, or acute psychiatric facilities that are supplying pharmacy services to patients receiving inpatient care (“Participating Inpatient Hospitals” or “PIHs”). Retail pharmacies are not eligible to participate in the Program
- PIHs must be validly licensed under applicable state law and do not accept Prescription Drug Marketing Act of 1987-compliant samples. PIH must notify Teva promptly if it begins accepting PDMA-compliant samples
- Program Product is being provided free of charge to be dispensed to patients receiving inpatient care and for use consistent with Program Product’s FDA-approved indication(s) (“Qualifying Patients”). PIHs will not bill the patient, the patient’s insurance carrier, or any government healthcare program for any product dispensed as part of the Program or for any administration services in connection with Program Product. PIHs must properly report the use of free-of-charge Program Product where drug costs are included in a capitated rate or there is submission of a cost report or other insurer or government program reporting requirements
- Program Product may not be sold, resold, traded, or distributed for sale
- Program Product will be dispensed only with a valid order from a provider licensed or authorized under state law to prescribe the product requested. The prescribing provider must be identified at the time the Program Product is ordered
- PIHs will provide Program Product only to Qualifying Patients. PIHs must ensure that prescribing providers and hospital employees understand the FDA-approved indications for WELTRUZA and that prescribing decisions are made in the best interest of the patient
- PIHs may only administer Program Product to Qualifying Patients if the prescriber has independently determined that the Program Product is clinically appropriate for that patient and that immediate onsite treatment with Program Product increases the long-term likelihood of a positive treatment outcome
- PIHs must complete and return a written receipt upon delivery of Program Product
- PIHs may request and receive trial units up to the Program limits
- PIHs must have adequate controls to track utilization of Program Product by each patient and must establish adequate controls to ensure that Program Product is appropriately segregated and tracked to ensure compliance with these terms and conditions
- PIHs, prescribing providers, and patients, as applicable, are under no obligation to prescribe, continue using, or recommend Teva products, including Program Product, as a condition of receiving any Program Product
- Program Product is commercially labeled as trade product and not labeled as samples
- The Program terminates on [December 31, 2025]. However, Teva reserves the right to terminate the Program at any earlier date. Teva will endeavor to provide notice of any such early termination as early as possible
- Program registrant’s name and the free trial disbursements may be reported as required by state or federal law. Once reported, this information may be made publicly available
To register or log in, review enrollment criteria, and read the full HIFTP Terms and Conditions, visit weltruza.inpatientrxtrial.com.
